Business Wire

IBC2018 Announces Telco and Media Innovation Forum amidst Plans for Record-Breaking Attendance

Del

IBC2018, the world’s most influential media, entertainment and technology show – which last year attracted more than 57,000 attendees from 170 countries – today announces an all-new Telco and Media Innovation Forum to expand its position as one of the preeminent destinations for telecoms and emerging technologies. The collaboration will form part of the prestigious annual IBC show at the RAI in Amsterdam from Thursday 13 to Tuesday 18 September 2018.

IBC2018’s focus on telecoms and smart connectivity comes at a time when the media and telecoms industries are becoming increasingly intertwined. Mirroring this trend, a cross-section of new and long-time IBC exhibitors will showcase the latest breakthroughs set to define both industries.

To reflect the ways in which emerging network technology is changing how the media world operates, IBC2018 will feature the dedicated Telco and Media Innovation Forum designed for the leading players in the industry and a new ‘Smart Connectivity and Multiplay Devices’ track within the IBC Conference Programme in order to provide a platform for collaborative dialogue between telecoms providers, media players and the OTT sector.

The exclusive Telco and Media Innovation Forum will include keynotes from Matt Stagg, Director of Mobile Strategy at BT Sport, Jeremy Fox, Co-founder & CEO, Atrium TV who will discuss how content is developing and how telecoms providers are benefitting from joining their club, and Domingo Corral Lopez, Director of Original Programming, Movistar who will give insight into how his business is developing original content under the wider Telefonica brand. This invitation-only programme will bring together C-suite level audience members to examine the collaboration between telecoms players and content providers, digital transformation, OTT content and current challenges around the evolution of the telecoms sector.

The ‘Smart Connectivity and Multiplay Devices’ track will tackle the challenges and opportunities offered by 5G, exploring the impact the technology will have on broadcasting and beyond. Speakers include Dr David Gomez-Barquero, Senior Researcher, Ramon & Cajal Fellow, Universitat Politecnica de Valencia and Dr Athul Prasad, Head of 5G Business Modelling & Analysis, Nokia - both from the 5G X-Cast consortium - who will deliver a focused masterclass on the future 5G network architecture for live scale immersive media delivery. Nicholas Wodtke, Executive VP, Digital Content, VEON will also give a case study around value added services, the role of content and how traditional mobile services are being disrupted.

IBC2018 is collaborating with the TM Forum - a non-profit industry association for service providers and their suppliers in the telecommunications sector - to increase cooperation and collaboration between their respective industries. TM Forum’s members generate over $2 trillion in revenue and serve five billion customers across 180 countries. The venture will encourage senior executives from both sectors to partner, helping broadcasters, operators and software vendors to work together across the media and telecoms sectors.

“IBC is the go-to destination for media technology professionals, attracting almost 60,000 people to Amsterdam each September. At IBC2018 we are launching the IBC Telco and Media Innovation Forum. Working with the TM Forum and others, IBC will to bring together C-level executives to explore the opportunities and challenges created by convergence,” said IBC CEO Michael Crimp. “We promise our hosted delegates a high-level networking event with world class content. I am sure this will be valuable day for all our guests. I am looking forward to being part of this new initiative.”

“Joining the biggest businesses in the telecoms and media spaces provides me with an opportunity to meet the most influential voices in each field – as a broadcaster looking at the role of mobile and our future, that’s vital,” commented Matt Stagg, Director of Mobile Strategy at BT Sport. “It’s important that events like this break down the silos of technologies and industries – this programme reflects the reality of broadcasting today.”

## ENDS ##

About IBC

IBC is the world’s most influential media, entertainment and technology show, attracting 57,000+ attendees from more than 170 countries and combining a highly respected and peer-reviewed conference with an exhibition that showcases 1,700+ leading industry suppliers of state-of-the-art technology. In addition to the world-class exhibition and conference, IBC also encompasses the IBC Daily, IBCTV and IBC365.

IBC365 provides year-round insight and opinion into the hot topics and key trends from leading industry journalists, along with insightful whitepapers, peer reviewed technical papers, highly engaging webinars and an expansive video library.

IBC2018 Dates

Conference:       13 - 17 September 2018
Exhibition: 14 - 18 September 2018

For more information about IBC2018 visit: show.ibc.org/

Contact information

Liberty Communications
Sophie Howell
IBC@libertycomms.com
+44 207 751 4444

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors17.6.2019 16:00:00 CESTPressemelding

Boehringer Ingelheim and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) today announce that the first patient has been dosed in the first-in-human Phase 1 clinical trial evaluating BI 765063, formerly OSE-172, a first-in-class monoclonal antibody antagonist of SIRPα, being studied in patients with advanced solid tumors. The Phase 1 study is a dose finding study of BI 765063, a myeloid checkpoint inhibitor, administered as a single agent and in combination with Boehringer Ingelheim’s monoclonal antibody PD-1 antagonist BI 754091, a T-lymphocyte checkpoint inhibitor. “We are very pleased with the progress achieved on BI 765063’s program and having the first patient dosed marks a significant milestone in the product’s development. The advancement of a myeloid cell checkpoint blocking monoclonal antibody into the clinic exemplifies Boehringer Ingelheim’s commitment to the next wave of innovation in cancer immunology therapies, with the goal of meaningfully improving outcomes fo

MagicStay Raises €3 Million to Accelerate Its International Development17.6.2019 15:58:00 CESTPressemelding

The apartment rental platform dedicated to business travelers, MagicStay.com , announces its full integration into the main business travel booking tools and a €3 million A-series to pursue its development, bringing the amounts raised to more than €8 million since its launch in 2013. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005644/en/ William Lecerf and Valéry Linyer, co-founders of MagicStay (Photo: MagicStay) "This fundraising will allow us to recruit talent to accelerate our growth. We want to sign a quarter of the major French companies and approach one million homes before the end of the year, thanks to the exclusive technologies we now have at our disposal", says Valéry Linÿer, CEO and co-founder, who adds: "We have four main advantages over our competitors: we meet the challenges of duty of care, we are able to customize our tool to meet the constraints of each large company for short and long stays, we ha

EURid Shows a 94% Reduction of Its Footprint since 201217.6.2019 15:32:00 CESTPressemelding

EURid, the not-for-profit organisation that operates the .eu and .ею top-level domains, is the first European TLD registry that registered for the EU Eco-Management and Audit Scheme (EMAS) from 2011. Since then, EURid has regularly assessed the environmental impact of its activities and monitored the compliance of its policies and procedures. As over the past four years, in Q2 2019 EURid was audited for the CO2 emissions of the previous year, resulting in an overall footprint of 135 tons CO2eq, which shows a 94% reduction since 2012. “We have achieved carbon neutrality via several actions and the compensation of the audited emissions. We were and are still among the first in our sector to report on our commitment to protect the environment”, commented CEO Marc Van Wesemael. Through EMAS, EURid has had the opportunity to support a multitude of global sustainability initiatives, like the Ugandan Borehole Project, Ecomapuà Project in the Amazon, the Dak Rung Hydropower Project in Vietnam,

Animation, Sound & Vibration – How Visa is Reinforcing Consumer Trust in a Changing Payments World17.6.2019 15:00:00 CESTPressemelding

Visa (NYSE: V) today announced global adoption of its sensory branding suite in 25 countries via more than a dozen new partnerships. The suite is comprised of sound, animation and haptic brand cues that occur with a Visa payment transaction. In a digital world increasingly filled with voice-commands, networked appliances and unattended retail environments, Visa’s sensory branding cues offer new ways to enhance the customer experience and convey the trust and security that the Visa brand represents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005240/en/ Visa was the first major payment brand to introduce multi-sensory branding, which included animation, sound and haptic vibration expressions of its brand. After an extensive creation and selection process that involved focus groups and elimination rounds, Visa landed on a single ‘energetic’ and ‘optimistic’ sound, and complementary animation and haptic vibration. Sinc

Study from Project Management Institute Identifies Six AI Technologies Impacting Project Professionals17.6.2019 14:40:00 CESTPressemelding

Project Management Institute (PMI) today released its 2019 Pulse of the Profession® In-Depth Report: AI Innovators: Cracking the Code on Project Performance. The report provides an in-depth look at how artificial intelligence (AI) is impacting organizations and the project management profession. Findings reveal that AI disruption is happening and at a large scale: 81 percent of respondents report their organization is being impacted by AI technologies; 37 percent say adopting AI technologies is a high priority for their organization; and project professionals say they expect the proportion of the projects they manage using AI will jump from 23 to 37 percent over the next three years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190617005558/en/ These insights from a survey of 551 project management practitioners globally show that the presence of AI technologies will continue to grow, requiring shifts in how projects are m

RIBOMIC Announces Positive Top-Line Results from the Phase 1/2a Clinical Trial of RBM-007 (SUSHI Study) in Subjects with Wet Age-Related Macular Degeneration17.6.2019 13:15:00 CESTPressemelding

RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (Code Number: 4591), today announced positive top-line results from its SUSHI study, Phase 1/2a single ascending dose clinical study of RBM-007, anti-FGF2 aptamer, in nine subjects with wet Age-Related Macular Degeneration (wet AMD). SUSHI study achieved the primary endpoint of safety and tolerability, and also demonstrated efficacy trends in favor of RBM-007. Subjects recruited for the SUSHI Study had wet AMD that was poorly responsive to previous intravitreal anti-VEGF therapy. Through the 56-Day exit visit, excluding one uncompleted case in the last cohort, single dose of RBM-007 demonstrated no dose-limiting toxicities, no systemic or ocular serious adverse events. One subject in Cohort 3 showed anterior inflammation, which was resolved after one day of topical prednisolone treatment. Rescue treatment with anti-VEGF therapy was ava